TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00117962
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
Study: NCT00506389
Drug: Esmirtazapine
Normalized name: Esmirtazapine
DrugBank: Esmirtazapine (DB06678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
Study: NCT01057628
Drug: ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral
Study: NCT01011257
Drug: Asprin
Normalized name: Easprin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
Study: NCT01011257
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 75 mg bid
Study: NCT03427437
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
Study: NCT03427437
Drug: Adrenalin
Normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
Study: NCT00249379
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
Study: NCT01217606
Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
Study: NCT01217606
Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
Study: NCT00753636
Drug: Dynacirc CR (Isradipine)
Normalized name: water
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
Study: NCT00638872
Drug: Polydeoxyribonucleotide
Normalized name: Polydeoxyribonucleotide synthase (ATP)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a week perilesional or intramuscular injections
Study: NCT00702624
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single injection of 100 μg corifollitropin alfa administered under protocol P05690
Study: NCT00702624
Drug: gonadatropin releasing hormone (GnRH) antagonist ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
Study: NCT00702624
Drug: placebo-corifollitropin alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
Study: NCT00023348
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023348
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03089567
Drug: Sodium Fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
Study: NCT03089567
Drug: Silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
Study: NCT02506777
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00469508
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg pills taken orally daily for 12 wks.
Study: NCT00476086
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00476086
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04332744
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
Study: NCT04332744
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
Study: NCT03037944
Drug: Yasmin
Normalized name: Yasmin
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
Study: NCT02974361
Drug: Ibuprofen Lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02406144
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02406144
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04134897
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2 iv day 1, 4 cycles
Study: NCT02182284
Drug: low dose BI 201335 NA soft gelatine capsule (SGC)
Normalized name: ritonavir
DrugBank: Gelatin (DB11242)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02182284
Drug: high dose BI 201335 NA soft gelatine capsule (SGC)
Normalized name: ritonavir
DrugBank: Gelatin (DB11242)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02182284
Drug: low dose BI 201335 NA powder in bottle (PIB)
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02182284
Drug: high dose BI 201335 NA powder in bottle (PIB)
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01229228
Drug: Naprosyn
Normalized name: Naprosyn
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT00288496
Drug: polyethylene glycol bowel lavage solution
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000597
Drug: antilymphocyte serum
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000597
Drug: nandrolone
Normalized name: Nandrolone
DrugBank: Nandrolone (DB13169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02747940
Drug: flunarizine and/or pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00110240
Drug: vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01699997
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal spray with 40 IU of OXT
Study: NCT00242879
Drug: Physician determined comparator PI + ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00242879
Drug: GW640385 + ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01001585
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
Study: NCT00996840
Drug: SB-681323 Intravenous 3mg
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg SB-681323 Intravenous administration infused over 4 hours
Study: NCT00996840
Drug: SB-681323 Intravenous 10mg
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SB-681323 Intravenous administration infused over 24 hours
Study: NCT02914626
Drug: Intravitreal ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal ranibizumab injection
Study: NCT02353949
Drug: Flutemetamol (Vizamyl)
Normalized name: FLUTEMETAMOL
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
Study: NCT03936426
Drug: Cu-64 SARTATE and Cu-67 SARTATE
Normalized name: CU-64 SARTATE
DrugBank: Cu-64 sartate (DB18170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
Study: NCT02494141
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement
Study: NCT01335971
Drug: Sulforaphane 25
Normalized name: SULFORAPHANE
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micromoles (4.4 mg) sulforaphane daily by mouth
Study: NCT03467620
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
Study: NCT01475955
Drug: Broad Area ALA 1-hour incubation
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA, broad area, 1 hour incubation
Study: NCT01475955
Drug: Broad Area ALA 2 hour incubation
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA broad area 2-hour incubation
Study: NCT01475955
Drug: broad area ALA 3-hour incubation
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA broad area 3 hour incubation
Study: NCT00509366
Drug: Cisplatin & Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles
Study: NCT01475955
Drug: Spot ALA 2 hour incubation
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA spot 2 hour incubation
Study: NCT01475955
Drug: Vehicle PDT
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
Study: NCT01938183
Drug: Metronidazole tablet
Normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg metronidazole tablets
Study: NCT01938183
Drug: Metronidazole benzoate gel
Normalized name: Metronidazole Benzoate
DrugBank: Metronidazole benzoate (DB15759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
Study: NCT02872103
Drug: F-627
Normalized name: Rh g-csf fc fusion protein f-627
DrugBank: Efbemalenograstim alfa (DB18704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
Study: NCT00674011
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as part of standard of care or another research protocol
Study: NCT00812669
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00509366
Drug: Cisplatin & Pemetrexed
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles
Study: NCT00509366
Drug: Docetaxel & Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
Study: NCT01503021
Drug: SFP
Normalized name: SFP
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Study: NCT03487445
Drug: Selatogrel 8 mg
Normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
Study: NCT03487445
Drug: Selatogrel 16 mg
Normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
Study: NCT02941367
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02941367
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02941367
Drug: basal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT03941548
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Administered as 12 mg tablets.
Study: NCT03180736
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
Study: NCT03180736
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
Study: NCT03180736
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
Study: NCT00932464
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 240-mg oral tablet; single dose under fasted conditions
Study: NCT00932464
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 240-mg oral tablet; single dose with high-fat breakfast
Study: NCT00262405
Drug: zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00440323
Drug: SB-649868
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-649868 tablets will be available with dose strength of 5 and 25 mg.
Study: NCT00440323
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem capsules will be available with dose strength of 10 mg.
Study: NCT00509366
Drug: Pemetrexed & Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
Study: NCT00861185
Drug: senicapoc
Normalized name: Senicapoc
DrugBank: Senicapoc (DB06280)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
Study: NCT01671410
Drug: oral morphine
Normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral morphine for the treatment of neonatal abstinence syndrome
Study: NCT01671410
Drug: sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
Study: NCT01065935
Drug: ALN-RSV01
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by nebulization once daily for 5 days
Study: NCT00290472
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02621385
Drug: tradipitant
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: test agent
Study: NCT02621385
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: substrate for drug-drug interaction assessment
Study: NCT01242111
Drug: BMN 110
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
Study: NCT00117767
Drug: Terbinafine hydrochloride (HCl)
Normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
Study: NCT00117767
Drug: Griseofulvin
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin pediatric suspension o.d. administration
Study: NCT03619213
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg tablets given once daily, per oral use.
Study: NCT02416869
Drug: 4mg Dexamethasone submucosal
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 4mg of submucosal Dexamethasone
Study: NCT02416869
Drug: 8mg Dexamethasone submucosal
Normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 8mg of submucosal Dexamethasone
Study: NCT00442598
Drug: Glufosfamide
Normalized name: Glufosfamide
DrugBank: Glufosfamide (DB06177)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00359892
Drug: Obatoclax mesylate (GX15-070MS)
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg q2wks
Study: NCT02945982
Drug: Entecavir+Carvedilol
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
Study: NCT02945982
Drug: Entecavir+Carvedilol+ Fuzheng Huayu
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
Study: NCT01120639
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Study: NCT01235195
Drug: sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg capsule, single-dose
Study: NCT01235195
Drug: sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet, single-dose
Study: NCT00811252
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encapsulated tablets; daily; orally
Study: NCT00811252
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: encapsulated tablets; daily; orally
Study: NCT00481481
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunosuppression